Abstract
Background: Portable topical hemostats are needed across a spectrum that extends from superficial household cuts to compressible traumatic bleeding in austere environments. A patented polyethylene oxide formulation comprising liquid PEO-400, solid PEO-1500 and PEO-4000, and aqueous zinc and copper salts can be cast as a cylindrical stick. Existing records describe wound contraction, scab formation, antimicrobial activity, and lower semi-quantitative wound bleeding, but do not establish time to hemostasis or efficacy in severe hemorrhage. Methods: We performed a translational design analysis of the patent record and two prior publications, reconciled claims against the available endpoints, and converted the evidence into two target product profiles: a same-user multi-use household stick for minor external wounds and a single-casualty field applicator for repeated application during one care episode. Product architecture, failure modes, performance gates, and a staged verification programme were defined using current trauma guidance, device-risk principles, and benchmark hemostatic models. Results: The source formulation is compatible with twist-up or push-up dispensing and rapidly forms a hydrophilic film, but its hemostatic mechanism remains a testable hypothesis based on fluid sequestration, surface pressure, and barrier formation. Prior rat data showed differences between PEO-metal treatment (n=7) and untreated controls (n=11) on days 4, 5, and 7 and reported bleeding scores of + versus ++, respectively; these outcomes support continued development but cannot be interpreted as validated hemorrhage control. The principal reuse hazards are cross-contamination, dose variability, tip deformation, water uptake, and transfer of debris into the wound. A controlled advance mechanism, sacrificial tip removal, tamper-evident cap, and explicit single-user or single-casualty labelling are therefore essential. Conclusions: A solid PEO balm is a plausible delivery platform for minor superficial bleeding and subsequent wound protection. Claims for moderate, severe, junctional, or arterial bleeding require blood-contact testing and standardized large-animal hemorrhage studies against gauze-based comparators. The proposed validation pathway prevents premature field claims while preserving a practical route to a compact first-aid product.